Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03005 MAD in healthy subjects
NCT02271412Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Oct 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing LY03005 with Placebo (2 arms). Primary endpoint: Adverse Events. Started Oct 2014; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02271412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271412.